3IQV image
Deposition Date 2009-08-21
Release Date 2010-09-01
Last Version Date 2024-11-13
Entry Detail
PDB ID:
3IQV
Title:
Crystal Structure of human 14-3-3 sigma in Complex with Raf1 peptide (6mer) and stabilisator Fusicoccin
Biological Source:
Source Organism:
(Taxon ID: )Homo sapiens (Taxon ID: 9606)
Method Details:
Experimental Method:
Resolution:
1.20 Å
R-Value Free:
0.15
R-Value Work:
0.12
R-Value Observed:
0.12
Space Group:
C 2 2 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:14-3-3 protein sigma
Gene (Uniprot):SFN
Chain IDs:A
Chain Length:236
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:6-mer peptide from RAF proto-oncogene serine/threonine-protein kinase
Gene (Uniprot):RAF1
Chain IDs:B (auth: P)
Chain Length:6
Number of Molecules:1
Biological Source:
Modified Residue
Compound ID Chain ID Parent Comp ID Details 2D Image
CSO A CYS S-HYDROXYCYSTEINE
SEP B SER PHOSPHOSERINE
Primary Citation
Impaired binding of 14-3-3 to C-RAF in Noonan syndrome suggests new approaches in diseases with increased Ras signaling.
Mol.Cell.Biol. 30 4698 4711 (2010)
PMID: 20679480 DOI: 10.1128/MCB.01636-09

Abstact

The Ras-RAF-mitogen-activated protein kinase (Ras-RAF-MAPK) pathway is overactive in many cancers and in some developmental disorders. In one of those disorders, namely, Noonan syndrome, nine activating C-RAF mutations cluster around Ser(259), a regulatory site for inhibition by 14-3-3 proteins. We show that these mutations impair binding of 14-3-3 proteins to C-RAF and alter its subcellular localization by promoting Ras-mediated plasma membrane recruitment of C-RAF. By presenting biophysical binding data, the 14-3-3/C-RAFpS(259) crystal structure, and cellular analyses, we indicate a mechanistic link between a well-described human developmental disorder and the impairment of a 14-3-3/target protein interaction. As a broader implication of these findings, modulating the C-RAFSer(259)/14-3-3 protein-protein interaction with a stabilizing small molecule may yield a novel potential approach for treatment of diseases resulting from an overactive Ras-RAF-MAPK pathway.

Legend

Protein

Chemical

Disease

Primary Citation of related structures